Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viva Biotech HoldingsFRA:VB0 +6.67%43 Cash-to-Debt is 1.18 as of Jun. 2026, which is 46% above its 10-year median of 0.81. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.14 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, Viva Biotech Holdings ranks worse than 79.47% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Viva Biotech Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.18.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Viva Biotech Holdingscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Viva Biotech Holdings's Cash-to-Debt or its related term are showing as below:
FRA:VB0'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: 0.81 Max: 65.83
Current: 0.82
During the past 11 years, Viva Biotech Holdings's highest Cash to Debt Ratio was 65.83. The lowest was 0.24. And the median was 0.81.
FRA:VB0's Cash-to-Debt is ranked worse than 79.47% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs FRA:VB0: 0.82
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Viva Biotech Holdings Cash-to-Debt Related Terms
Viva Biotech Holdings Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:VB0 vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Cash-to-Debt of 1.18 as of Jun. 2026. This is 46% above median its historical median of 0.81. Over the past decade, Viva Biotech Holdings' Cash-to-Debt has ranged from 0.24 to 65.83. According to the industry distribution chart, Viva Biotech Holdings ranks #1107 out of 1393 companies in the Biotechnology industry, placing it in the top 79.5%.
Is Viva Biotech Holdings' Cash-to-Debt too high?
Viva Biotech Holdings' current Cash-to-Debt of 1.18 is 46% above median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 65.83. The Biotechnology industry median Cash-to-Debt is 7.03. Viva Biotech Holdings' value of 1.18 is 83.2% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #1107 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #1107 out of 1393 companies for Cash-to-Debt. This places Viva Biotech Holdings in the lower half of its industry. The industry median Cash-to-Debt is 7.03. Viva Biotech Holdings' value of 1.18 is 83.2% below this benchmark. Historically, Viva Biotech Holdings' own Cash-to-Debt has ranged from 0.24 to 65.83 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 7.03, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Cash-to-Debt of 1.18 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Cash-to-Debt is 1.18, which is 46% above median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.16 — trading 14.3% above its estimated fair value. The current Cash-to-Debt is 1.18, which is 46% above median its 10-year median of 0.81 and 83.2% below the Biotechnology industry median of 7.03. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Cash-to-Debt is 1.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.16 is trading 14.3% above its estimated GF Value™ of €0.14.
GuruFocus considers Viva Biotech Holdings to be Modestly Overvalued.
Key valuation signals for FRA:VB0:
Cash-to-Debt: 1.18 (46% above median its 10-year median of 0.81)
GF Value™: €0.14 vs. price of €0.16 (14.3% above fair value)
Industry Position: 83.2% below the Biotechnology median (#1107 of 1393)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score
Get the complete analysis for FRA:VB0
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
